Polatuzumab vedotin targets CD79b on B cells; after internalization, the linker is cleaved to release MMAE, which inhibits tubulin polymerization causing G2/M arrest and apoptosis. Tubulin is the intracellular payload target, not the antigen recognized by the drug, so cells expressing tubulin alone are not selectively killed.